Artificial intelligence (AI) has the potential to solve many of humanity’s problems at a pace that far exceeds the limitations of human intelligence. AI excels at detecting errors, minimizing bias, and accelerating decision-making.
Medicine is one industry that can benefit the most from AI. For example, the patient journey today involves trial and error from diagnoses through treatment; similarly, clinical drug development necessitates human experimentation. Fortunately, AI is improving the status quo, from aiding more accurate diagnoses to enabling smaller placebo arm sizes in clinical trials. But computer science experts say we’re only at the beginning of realizing AI’s full potential.
In this Endpoints webinar, hear from AI researcher Charles Fisher, founder and CEO of Unlearn, about the increasingly prominent role of AI medicine. Unlearn was founded to advance AI to eliminate trial and error in medicine, starting with their prognostic digital twins used in clinical trials today and with broader future applications in personalized medicine.
WHAT WILL BE COVERED IN THIS WEBINAR:
WHO SHOULD ATTEND THIS WEBINAR: